vs
Side-by-side financial comparison of Coeptis Therapeutics Holdings, Inc. (COEP) and Pineapple Financial Inc. (PAPL). Click either name above to swap in a different company.
Coeptis Therapeutics Holdings, Inc. is the larger business by last-quarter revenue ($862.0K vs $707.3K, roughly 1.2× Pineapple Financial Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -2756.2%, a 2609.7% gap on every dollar of revenue.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
COEP vs PAPL — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $862.0K | $707.3K |
| Net Profit | $-1.3M | $-19.5M |
| Gross Margin | 94.8% | 48.9% |
| Operating Margin | -230.6% | -2518.8% |
| Net Margin | -146.5% | -2756.2% |
| Revenue YoY | — | -4.8% |
| Net Profit YoY | 55.1% | -3174.1% |
| EPS (diluted) | $0.05 | $-1.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $707.3K | ||
| Q4 25 | $862.0K | $721.7K | ||
| Q3 25 | $237.4K | $730.5K | ||
| Q2 25 | $200.7K | $746.9K | ||
| Q1 25 | $62.9K | $743.3K | ||
| Q4 24 | $0 | $766.1K | ||
| Q3 24 | $0 | $598.3K | ||
| Q2 24 | $0 | $736.4K |
| Q1 26 | — | $-19.5M | ||
| Q4 25 | $-1.3M | $-6.4M | ||
| Q3 25 | $-2.9M | $-1.8M | ||
| Q2 25 | $-4.3M | $-557.7K | ||
| Q1 25 | $-3.4M | $-595.4K | ||
| Q4 24 | $-2.8M | $-656.9K | ||
| Q3 24 | $-1.8M | $-1.7M | ||
| Q2 24 | $-3.0M | $-848.6K |
| Q1 26 | — | 48.9% | ||
| Q4 25 | 94.8% | 49.6% | ||
| Q3 25 | 81.0% | 27.8% | ||
| Q2 25 | 77.5% | 67.6% | ||
| Q1 25 | 28.2% | 43.4% | ||
| Q4 24 | — | 45.9% | ||
| Q3 24 | — | 43.2% | ||
| Q2 24 | — | 44.2% |
| Q1 26 | — | -2518.8% | ||
| Q4 25 | -230.6% | -909.1% | ||
| Q3 25 | -1043.2% | -131.3% | ||
| Q2 25 | -2252.9% | -93.3% | ||
| Q1 25 | -6452.6% | -80.6% | ||
| Q4 24 | — | -90.5% | ||
| Q3 24 | — | -232.8% | ||
| Q2 24 | — | -121.7% |
| Q1 26 | — | -2756.2% | ||
| Q4 25 | -146.5% | -891.6% | ||
| Q3 25 | -1220.8% | -250.3% | ||
| Q2 25 | -2159.9% | -74.7% | ||
| Q1 25 | -5440.9% | -80.1% | ||
| Q4 24 | — | -85.7% | ||
| Q3 24 | — | -283.9% | ||
| Q2 24 | — | -115.2% |
| Q1 26 | — | $-1.21 | ||
| Q4 25 | $0.05 | $-4.79 | ||
| Q3 25 | $-0.58 | $-0.93 | ||
| Q2 25 | $-1.17 | $-0.05 | ||
| Q1 25 | $-1.11 | $-1.73 | ||
| Q4 24 | $-5.35 | $-2.60 | ||
| Q3 24 | $-0.05 | $-11.10 | ||
| Q2 24 | $-0.08 | $-0.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $676.6K | — |
| Total DebtLower is stronger | $150.0K | — |
| Stockholders' EquityBook value | $13.6M | $27.1M |
| Total Assets | $16.2M | $48.9M |
| Debt / EquityLower = less leverage | 0.01× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $676.6K | — | ||
| Q3 25 | $421.7K | — | ||
| Q2 25 | $990.6K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $150.0K | — | ||
| Q3 25 | $150.0K | — | ||
| Q2 25 | $150.0K | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $150.0K | — | ||
| Q3 24 | $1.7M | — | ||
| Q2 24 | $1.7M | — |
| Q1 26 | — | $27.1M | ||
| Q4 25 | $13.6M | $-5.5M | ||
| Q3 25 | $10.4M | $906.7K | ||
| Q2 25 | $6.1M | $842.6K | ||
| Q1 25 | $6.5M | $739.7K | ||
| Q4 24 | $3.4M | $1.3M | ||
| Q3 24 | $4.8M | $1.3M | ||
| Q2 24 | $-442.6K | $2.0M |
| Q1 26 | — | $48.9M | ||
| Q4 25 | $16.2M | $10.6M | ||
| Q3 25 | $14.2M | $5.4M | ||
| Q2 25 | $12.2M | $4.7M | ||
| Q1 25 | $13.5M | $4.0M | ||
| Q4 24 | $8.9M | $4.1M | ||
| Q3 24 | $9.0M | $4.1M | ||
| Q2 24 | $4.2M | $4.3M |
| Q1 26 | — | — | ||
| Q4 25 | 0.01× | — | ||
| Q3 25 | 0.01× | — | ||
| Q2 25 | 0.02× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.04× | — | ||
| Q3 24 | 0.35× | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-8.6M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.3M |
| FCF MarginFCF / Revenue | — | -462.7% |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $-3.3M | ||
| Q4 25 | $-8.6M | $-489.7K | ||
| Q3 25 | $-2.2M | $-507.6K | ||
| Q2 25 | $-2.4M | $397.0K | ||
| Q1 25 | $-2.4M | $-172.6K | ||
| Q4 24 | $-6.6M | $-663.6K | ||
| Q3 24 | $-1.9M | $-264.7K | ||
| Q2 24 | $-1.4M | $123.0K |
| Q1 26 | — | $-3.3M | ||
| Q4 25 | — | $-491.7K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-264.7K | ||
| Q2 24 | — | $122.7K |
| Q1 26 | — | -462.7% | ||
| Q4 25 | — | -68.1% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -44.2% | ||
| Q2 24 | — | 16.7% |
| Q1 26 | — | 0.0% | ||
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
